-
Mashup Score: 24Evaluating the Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs | JCO Oncology Practice - 22 hour(s) ago
PURPOSEDespite a universal public health care system, Canadian oncology patients often enroll in patient assistance programs (PAPs) to access oncology drugs that are awaiting funding decisions. Our multicenter study evaluated the pharmacoeconomic and …Our study assessed pharmacoeconomic benefits to patient assistance programs (PAPs) for oncology drugs in Canada.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 24Evaluating the Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs | JCO Oncology Practice - 1 day(s) ago
PURPOSEDespite a universal public health care system, Canadian oncology patients often enroll in patient assistance programs (PAPs) to access oncology drugs that are awaiting funding decisions. Our multicenter study evaluated the pharmacoeconomic and …Our study assessed pharmacoeconomic benefits to patient assistance programs (PAPs) for oncology drugs in Canada.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Evaluating the Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs: https://t.co/pstHZ27cHh #QoL
-
-
Mashup Score: 1Do preinjury life events moderate the outcomes of mild traumatic brain injuries in children? An A-CAP Study - 9 month(s) ago
AbstractObjective. To examine preinjury life events as moderators of postconcussive symptoms (PCS) and quality of life (QoL) in children with pediatric mild tra
Source: academic.oup.comCategories: General Medicine News, PediatricsTweet-
New in Advance Access: This study examined preinjury life events as moderators of postconcussive symptoms and quality of life #QoL in children with pediatric mild traumatic brain injury versus orthopedic injury. https://t.co/4pd8qidaUp
-
-
Mashup Score: 16
PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may inhibit our ability to understand patient toxicity burden. We analyze the relationship between the grades of AEs experienced with patient side-effect bother and treatment discontinuation. METHODS We analyzed a phase III Eastern Cooperative Oncology Group-American College of Radiology Imaging Network trial with comprehensive AE data. The Likert response Functional Assessment of Cancer Therapy-GP5 item, “I am bothered by side effects of treatment” was used to define side-effect bother. Bayesian mixed models were used to assess the impact of G1 and G2 AE counts on patient side-effect bother and treatment discontinuation. AEs were further analyzed on the basis of symptomatology (symptomatic or asymptomatic). The results are given as odds ratios (ORs) and
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
🧐 Grade 1 and 2 AEs are associated w/ increased odds of patient side effect burden & treatment dropout: https://t.co/jLqyu7mTD7 #QOL @NateOConnellPhD
-
-
Mashup Score: 4Quality of Life After Transcatheter Aortic Valve Replacement in Normal-Flow, Low-Gradient Aortic Stenosis: - 1 year(s) ago
Abstract Background Prior studies of aortic valve replacement (AVR) in patients with normal-flow, low-gradient aortic stenosis (NF-LG AS) have demonstrated conflicting results regarding the surviva…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
Selected patients with NF-LG AS experienced similar improvement in #QoL after #TAVR compared with HG-AS. Further investigation of patients with NF-LG AS will help to inform optimal selection for Tx with TAVR. https://t.co/QNjI4cftf8 #JACCAdvances #vhdAS #CardioTwitter https://t.co/SUXNHlFiJV
-
-
Mashup Score: 1Combination Therapy Improves Quality of Life in Advanced Stomach Cancer, Esophageal Cancer - 1 year(s) ago
Combining an immune checkpoint inhibitor with standard chemotherapy improved quality of life for patients with advanced stomach cancer or esophageal cancer compared to chemotherapy alone, according to recent findings published in The Journal of Clinical Oncology.
Source: news.feinberg.northwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“We have a win-win for patients.” Combining a PD-1 checkpoint inhibitor w/ chemotherapy improved quality of life for patients with advanced #stomachcancer or #esophagealcancer, according to findings from @LurieCancer’s David Cella, PhD, in @JCO_ASCO https://t.co/ZO5LmKQgyl #QoL
-
-
Mashup Score: 3
Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA Division of Cardiology, The Texas Heart Institute Center for Cardiovascular Care, Baylor St. Luke’s Medical Center, Houston, Texas, USA Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
Civility, collab, & mutual respect b/w workforce members are vital for overall success of healthcare delivery to pts. Bias, discrimination, bullying, & harassment lead to career-related repercussions & ⬇️ #QoL for healthcare professionals & their pts. https://t.co/lNdXs9WIGC… https://t.co/cO6hPy0C4t https://t.co/g4GnhS51wN
-
-
Mashup Score: 75-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results - 1 year(s) ago
Abstract Background The MITRAL (Mitral Implantation of Transcatheter Valves) trial is the first prospective trial to evaluate the safety and feasibility of balloon-expandable aortic transcatheter h…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
📌 The #MITRAL Trial results are in! 📚 5-yr prospective eval of mitral valve-in-valve (MViV), valve-in-ring (MViR), & valve-in-MAC (ViMAC) outcomes: all 3 w/ sustained improvement in #HeartFailure & #QoL, but MViV w/ much better survival. https://t.co/j50P7MaQ3O #JACCINT https://t.co/V50ybF7D0j
-
-
Mashup Score: 3
Abstract Despite advances in medical therapy for patients with stage C heart failure (HF), survival for patients with advanced HF is <20% at 5 years. Durable left ventricular assist device (dLVAD) ...
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
New #JACC Scientific Statement! Contemporary durable mechanical circulatory support improves survival, #QoL and functional capacity but is underutilized in the treatment of advanced #heartfailure. Read more from this crucial work: https://t.co/7TmhJKYsKU #CardioTwitter #LVAD https://t.co/3GVGlrbKZp
-
-
Mashup Score: 6Cella Named 2023 Tripartite Prize Recipient - 1 year(s) ago
David Cella, PhD, professor of Medical Social Sciences, has been named the winner of the 2023 Tripartite Legacy Faculty Prize in Translational Science and Education.
Source: news.feinberg.northwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us in congratulating David Cella, PhD, Associate Director for Cancer Prevention and Control @LurieCancer, on winning the 2023 Tripartite Prize. Read about his trailblazing work amplifying the patient voice: https://t.co/SmjPFZNwaw #QoL #PROs https://t.co/D92VtIPvFh
-
Evaluating the Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs: https://t.co/pstHZ27cHh #QoL